Key result
Coronary sinus Reducer implantation significantly improved left ventricular ejection fraction from 61% to 66% (p=0.009) at 4 months in patients with refractory angina.
Why the study?
Coronary sinus Reducer implantation provides symptomatic relief in refractory angina, but its effects on left ventricular function remained unknown.
Does coronary sinus Reducer implantation improve left ventricular function in patients with refractory angina pectoris?
Observational (n=19)
Does coronary sinus Reducer implantation improve left ventricular function in patients with refractory angina pectoris?
Coronary sinus Reducer implantation in patients with refractory angina is associated with significant improvements in left ventricular ejection fraction and myocardial perfusion at 4 months.
Should not yet change practice for LV function; leaves open randomized confirmation of Reducer LVEF effects.
Objectives To evaluate the impact of coronary sinus (CS) Reducer implantation upon left ventricular (LV) function. Background CS Reducer implantation is associated with symptomatic relief in patients with refractory angina. The effects of the device upon left ventricular function remains unknown. Methods Prior to device implantation and at 4‐months, resting ventricular volumes and function were measured using cardiac magnetic resonance (CMR). Stress CMR was performed to extract quantitative indices of myocardial perfusion (myocardial perfusion reserve index‐MPRI). Results Nineteen patients (18 males, 66.0 [IQR 56.0–77.0] years), underwent successful Reducer implantation. Sixteen (84%) patients improved by at least 1 CCS class. Four months after Reducer implantation, we noticed a significant improvement in LV ejection fraction (LVEF) (61 [IQR 47–71] to 66 [IQR 57–72] %; p = .009), a reduction in LV end‐diastolic volume (LVEDV)/Body surface area (BSA) (65.7 [IQR 57.4–89.6] to 64.7 [IQR 53.7–74.1] mL/m 2 ; p = .036) and a reduction in LV end‐systolic volume (LVESV)/BSA (28.7 [IQR 18.6–38.8] to 20.0 [IQR 15.0–31.4] mL/m 2 ; p = .007). Patients with reduced EF (EF < 50%, n = 6) presented a greater increase of EF at follow up compared to patients with preserved EF (11.3 [IQR 6.5–54.5] vs. 3.8 [IQR 0.6–9.1] %; p = .029). The observed decrease in LVESV/BSA was greater in patients with reduced EF (23.6 [IQR 11.6–33.8] vs. 4.2 [IQR −2.0 to 8.4] mL/m 2 ; p = .005). A significant increase in transmural MPRI was observed 4 months after Reducer implantation ( p < .011). Conclusions CS Reducer improved angina symptoms and improved left ventricular function. The improvement was pronounced in the subgroup of patients with reduced ejection fraction. Myocardial perfusion improvement could represent the underlying mechanism for the observed benefits.
No takes yet. Share an insight, caveat, or question.
Tzanis et al. (2019) conducted an observational in refractory angina pectoris (n=19). Coronary sinus Reducer implantation vs. Baseline was evaluated on Left ventricular ejection fraction (LVEF) (p=.009). Coronary sinus Reducer implantation significantly improved left ventricular ejection fraction from 61% to 66% (p=0.009) at 4 months in patients with refractory angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: